Use of monoclonal antibodies in vivo as a therapeutic strategy for alloimmune or autoimmune reactivity: the Besançon experience

Immunol Rev. 1992 Oct:129:31-55. doi: 10.1111/j.1600-065x.1992.tb01418.x.

Authors

P Herve¹, E Racadot, D Wendling, L Rumbach, P Tiberghien, J Y Cahn, M Flesch, J Wijdenes

Affiliation

¹ Bone Marrow Transplantation Unit, Hospital Jean Minjoz, Besançon, France.

PMID: 1464420
DOI: 10.1111/j.1600-065x.1992.tb01418.x

No abstract available

Publication types

Clinical Trial
Clinical Trial, Phase I
Clinical Trial, Phase II
Multicenter Study
Research Support, Non-U.S. Gov't
Review

MeSH terms

Adult
Aged
Antibodies, Monoclonal / therapeutic use*
Arthritis, Rheumatoid / therapy
Autoimmune Diseases / therapy*
Bone Marrow Transplantation
Cytokines / immunology
Graft vs Host Disease / therapy*
Humans
Middle Aged
Multiple Sclerosis / therapy
Pilot Projects
Receptors, Interleukin-2 / immunology*
T-Lymphocytes / immunology*

Substances

Antibodies, Monoclonal
Cytokines
Receptors, Interleukin-2